Post-ASH 2021 iwNHL

27–28 January 2022 | Virtual Meeting

Post-ASH 2021 iwNHL

27–28 January 2022 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in Non-Hodgkin Lymphoma (NHL) from ASH 2021

The Post-ASH 2021 iwNHL Virtual Workshop was held on 27-28 January 2022. The program covered key topics in the area of non-Hodgkin lymphoma. Both days featured a series of short presentations from invited experts on selected abstracts from the 63rd ASH Annual Meeting with interactive panel discussions after each session.

Session 1: NHL; Follicular Lymphoma
Anand Jeyasekharan
Ex-vivo platform for choice of drug combinations in R/R lymphoma
Anand Jeyasekharan National University of Singapore, Singapore, Singapore
Matthew Maurer
FLIPI24: EFS & OS in patients with FL treated with immunochemotherapy
Matthew Maurer Mayo Clinic, Rochester, MN, United States
Joseph Schroers-Martin
Detectable tumor-confirmed FL mutations in PB years prior to clinical diagnosis
Joseph Schroers-Martin Stanford University, Stanford, CA, United States
Craig Portell
Frontline VEN+OBI and BEN in high tumor burden FL
Craig Portell University of Virginia, Charlottesville, VA, United States
Andrew Weng
Cell-of-origin risk stratification prior to immune profiling of DLBCL biopsies
Andrew Weng BC Cancer Agency, Vancouver, Canada
Vincent Ribrag
MCL R2 Elderly: R2 vs RTX maintenance after immunochemotherapy in MCL
Vincent Ribrag Gustave Roussy Institute, Villejuif, France
Session 1 panel discussion
Session 2: Novel Therapies
Hervé Tilly
POLARIX: pola-R-CHP vs R-CHOP in previously untreated DLBCL
Hervé Tilly Henri Becquerel Center, Rouen, France
Elizabeth Budde
Mosunetuzumab monotherapy in patients with R/R FL with ≥2 prior LoT
Elizabeth Budde City of Hope, Duarte, CA, United States
Mark  Roschewski
ACA prior to frontline therapy in untreated aggressive B-cell lymphoma
Mark Roschewski National Cancer Institute, Bethesda, MD, United States
Martin  Hutchings
Glofitamab + polatuzumab vedotin in R/R DLBCL
Martin Hutchings Copenhagen University Hospital, Copenhagen , Denmark
Julio Chavez
Global Unity-NHL: umbralisib plus ublituximab in R/R MZL
Julio Chavez Moffitt Cancer Center, Tampa, FL, United States
Ryan Lynch
CITADEL-203: parsaclisib in R/R FL
Ryan Lynch Seattle Cancer Care Alliance, Seattle, WA, United States
Session 2 panel discussion
Session 3: CLL & SLL
Paolo Ghia
DFS results from MRD cohort of Captivate
Paolo Ghia Vita-Salute San Raffaele University, Milan, Italy
Barbara Eichhorst
GAIA (CLL13): VEN-based time-limited combination treatments vs SOC in CLL
Barbara Eichhorst University Hospital Cologne, Cologne , Germany
Talha Munir
NCRI FLAIR: IBR+RTX vs FCR in previously untreated CLL
Talha Munir Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Matthew Davids
MAJIC: frontline ACA+VEN vs VEN+OBI in CLL or SLL
Matthew Davids Dana-Farber Cancer Institute, AL, United States
Alessandra  Tedeschi
SEQUOIA: frontline ZAN+VEN in CLL or SLL with del(17p)
Alessandra Tedeschi Niguarda Cancer Center, Milan, Italy
Constantine Tam
SEQUOIA: ZAN vs BEN+RTX in treatment-naïve CLL/SLL
Constantine Tam Peter MacCallum Cancer Centre, Victoria, Australia
Wojciech  Jurczak
Ascend: ACA vs RTX+IDL or BEN in R/R CLL
Wojciech Jurczak Maria Skłodowska-Curie Institute of Oncology, Warsaw, Poland
Talha Munir
Glow: MRD outcomes after fixed-duration IBR+VEN vs CLB+OBI in CLL
Talha Munir Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Session 3 panel discussion
Session 4: T-Cell Engagement & Therapies
Manali Kamdar
Transform: liso-cel vs SOC + salvage chemotherapy and ASCT in R/R LBCL
Manali Kamdar University of Colorado Cancer Center, Denver, CO, United States
Sattva  Neelapu
ZUMA-5: axi-cel in patients with R/R iNHL
Sattva Neelapu University of Texas MD Anderson Cancer Center, Houston, TX, United States
Catherine Thieblemont
Elara: tisa-cel in adult patients with high-risk R/R FL
Catherine Thieblemont Saint-Louis Hospital, Paris, France
Ian  Flinn
First-in-human study of YTB323 CAR-T therapy in patients with R/R DLBCL
Ian Flinn Sarah Cannon Research Institute, Nashville, TN, United States
Matthew Frank
High durable remission rates after CD22-CAR-T therapy in adults with R/R LBCL
Matthew Frank Stanford University, Stanford, CA, United States
Yucai Wang
Real-world data from US Lymphoma CAR T Consortium: brexu-cel for R/R MCL
Yucai Wang Mayo Clinic, Rochester, MN, United States
Natalie Grover
CD30-directed CAR-Ts co-expressing CCR4 in R/R HL and CD30+ CTCL
Natalie Grover UNC School of Medicine, Chapel Hill, NC, United States
Session 4 panel discussion

Meeting Supporters: 


Visit The Lymphoma channel for the latest updates from leading experts

 

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter